title: Concerns about Provenge simmer as CMS ponders coverage.
authors.forename: Merrill
authors.initials: M
authors.lastname: Goozner
mesh_terms: D026683:Advisory Committees; D000726:Androgen Antagonists / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use*; D015986:Confounding Factors, Epidemiologic; D018572:Disease-Free Survival; D017277:Drug Approval; D019317:Evidence-Based Medicine; D006801:Humans; D008297:Male; D008484:Medicaid; D006278:Medicare; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality / Q000517:prevention & control; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D014020:Tissue Extracts / Q000627:therapeutic use*; D014481:United States / Q000453:epidemiology; D014486:United States Food and Drug Administration
chemical_list: D000726:Androgen Antagonists; D019496:Cancer Vaccines; D014020:Tissue Extracts; C511774:sipuleucel-T; D017430:Prostate-Specific Antigen